GANX
Gain Therapeutics, Inc.
Biotechnology · Healthcare · United States
1.13
close · 2026-10-30
value
14
cheaper than peers14
quality
21
stronger fundamentals21
ranked against
Biotechnology (pre-revenue)
value
quality
109 peerswide variation
Value inputs
| measure | company | vs peers |
| earnings yield, 3 years ago | -131.0% | 33 |
| cash flow yield, 3 years ago | -30.0% | 33 |
| price to book | 4.33× | 33 |
| cash flow yield, 1 year ago | -38.3% | 32 |
| cash flow yield, latest year | -37.4% | 31 |
| earnings yield, latest year | -54.0% | 30 |
| cash flow yield, 2 years ago | -38.3% | 28 |
| earnings yield, 1 year ago | -78.8% | 27 |
| earnings yield, 2 years ago | -151.3% | 24 |
9 of 12 measures available
Quality inputs
| measure | company | vs peers |
| operating margin | 0.0% | 50 |
| debt to equity | 5.4% | 48 |
| return on equity | -268.3% | 9 |
3 of 4 measures available
Facts
| market cap | $49M |
| free cash flow | -$11.1M |
| employees | 20 |
| first trade | 2021-03-19 |
| next earnings | not reported |
| fundamentals updated | 2026-08-18 |
Annual history
| measure | 2025 | 2024 | 2023 | 2022 |
| diluted eps | -0.61 | -0.89 | -1.71 | -1.48 |
| free cash flow | -$18.5M | -$18.9M | -$18.9M | -$14.8M |
| net income | -$20.2M | -$20.4M | -$22.3M | -$17.6M |
| revenue | $0 | $0 | $55,180 | $140,108 |
| unusual items | -$833,673 | $119,120 | -$429,346 | -$96,074 |